Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05722561 · ClinicalTrials.gov registry record · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
A Phase 2 study of Opioid Use Disorder and Cigarette Smoking, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 302
- Enrollment target
- 2
- Study locations
NCT05722561: Recruiting Phase 2 study of Opioid Use Disorder and Cigarette Smoking, sponsored by NYU Langone Health.
NCT05722561 is a Phase 2 study of Opioid Use Disorder and Cigarette Smoking that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 302 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05722561, a Phase 2 study of Opioid Use Disorder and Cigarette Smoking, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 302 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this an open-label, randomized controlled trial study is to compare the effectiveness of electronic cigarettes (e-cigarettes/e-cigs) versus telehealth motivational counseling with combination nicotine replacement therapy (NRT) + telehealth counseling on combustible cigarettes smoking reduction among persons with opioid use disorder (OUD) in methadone and buprenorphine treatment programs (opioid use disorder treatment programs (OUDTP)). OUDTP patients are a population with exceptionally high combustible cigarettes smoking burden and yet limited success in achieving meaningful clinical outcomes in tobacco treatment. If effective, electronic cigarettes would provide an additional tool for tobacco harm reduction among this difficult-to-treat vulnerable population.
Primary Outcome
Verified by exhaled carbon-monoxide (eCO) level.
Conditions Studied
Interventions
- BEHAVIORAL Telehealth Motivational Counseling
- DRUG Nicotine Replacement Product
- DEVICE National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).
Study Locations (2)
New York
- NYU Langone Health - New York
- Albert Einstein College of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
What NCT05722561 shows while recruiting
NCT05722561 is an interventional study that assigns participants to a tested intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Telehealth Motivational Counseling is the first listed.
NCT05722561 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05722561 about?
NCT05722561 is a clinical study titled "E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder". The purpose of this an open-label, randomized controlled trial study is to compare the effectiveness of electronic cigarettes (e-cigarettes/e-cigs) versus telehealth motivational counseling with combination nicotine replacement therapy (NRT) + telehealth counseling on combustible cigarettes smoking ...
What is the current status of trial NCT05722561?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 302 participants. The study started on 2024-08-08. Estimated completion is 2027-03-01.
What conditions does trial NCT05722561 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Cigarette Smoking.
What interventions are being tested in trial NCT05722561?
The interventions under investigation include: Telehealth Motivational Counseling (BEHAVIORAL), Nicotine Replacement Product (DRUG), National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC). (DEVICE).
Who is sponsoring clinical trial NCT05722561?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05722561 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05722561's enrollment target sits among peer trials
302 56th of 257 higher than 202 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Remotely Observed Methadone Evaluation II
RECRUITING · Phase 2
-
Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
RECRUITING · Phase 2
-
Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose
RECRUITING · Phase 2
-
Ketamine for Opioid Use Disorder
RECRUITING · Phase 2
-
Brief Digitally-Enhanced Intervention for Reducing Alcohol Use During MOUD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
- NCT05005975 · 301 participants · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI